caa a22 4500 477061974 CHVBK 20180405111403.0 cr unu---uuuuu 170330e19961201xx s 000 0 eng 10.1007/BF00133082 doi (NATIONALLICENCE)springer-10.1007/BF00133082 Comparison of the pharmacokinetics and effects on the hemostatic system of saruplase and urokinase in patients with acute myocardial infarction [Elektronische Daten] [Joerg Poeppelmeier, Horst Beier, Joerg Carlsson, Wolfgang Guenzler, Rainer Meierhenrich, Gwyn Hopkins, Ulrich Tebbe] The aim of the study was to compare in a single trial, using identical methodology, the pharmacokinetic properties and the effect on the hemostatic system of saruplase (unglycosylated scu-PA) and urokinase (glycosylated tcu-PA). Twenty-four patients with an acute myocardial infarction were either treated with saruplase (n = 12; 20 mg IV bolus followed by a 60 mg infusion for 60 minutes) or urokinase (n = 12; 1.5 million IU IV bolus followed by 1.5 million IU infusion for 60 minutes). Blood samples from saruplase-treated patients were analyzed for u-PA antigen and total u-PA and tcu-PA activities; those from urokinase-treated patients for u-PA antigen and tcu-PA activity. The effect of treatment on, including recovery of, plasma α2-antiplasmin, fibrinogen, and plasminogen was examined in both groups. The total clearance of urokinase (179 ± 55 ml/ min) is about half that of saruplase (406 ± 154 ml/min), and the mean residence time of urokinase (59.1 ± 22.5 minutes) is nearly twice that of saruplase (28.3 ± 7.8 minutes), which results in a slower elimination of urokinase from plasma. Whether differences in the pharmacokinetic behavior of the unglycosylated saruplase and the glycosylated urokinase observed in this study are due to the difference in glycosylation or to other factors is not resolved. The systemic effect of saruplase on α2,-antiplasmin, fibrinogen, and plasminogen is similar to that of urokinase, although retarded. Kluwer Academic Publishers, 1996 saruplase nationallicence urokinase nationallicence pharmacokinetics nationallicence hemostasis nationallicence Poeppelmeier Joerg Medizinische Klinik II, Klinikum Lippe-Detmold, Germany aut Beier Horst Gruenenthal GmbH, Aachen, Germany aut Carlsson Joerg Medizinische Klinik II, Klinikum Lippe-Detmold, Germany aut Guenzler Wolfgang Gruenenthal GmbH, Aachen, Germany aut Meierhenrich Rainer Medizinische Klinik II, Klinikum Lippe-Detmold, Germany aut Hopkins Gwyn Gruenenthal GmbH, Aachen, Germany aut Tebbe Ulrich Medizinische Klinik II, Klinikum Lippe-Detmold, Germany aut Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 3/4(1996-12-01), 385-390 0929-5305 3:4<385 1996 3 11239 https://doi.org/10.1007/BF00133082 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00133082 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Poeppelmeier Joerg Medizinische Klinik II, Klinikum Lippe-Detmold, Germany aut NATIONALLICENCE 700 1- Beier Horst Gruenenthal GmbH, Aachen, Germany aut NATIONALLICENCE 700 1- Carlsson Joerg Medizinische Klinik II, Klinikum Lippe-Detmold, Germany aut NATIONALLICENCE 700 1- Guenzler Wolfgang Gruenenthal GmbH, Aachen, Germany aut NATIONALLICENCE 700 1- Meierhenrich Rainer Medizinische Klinik II, Klinikum Lippe-Detmold, Germany aut NATIONALLICENCE 700 1- Hopkins Gwyn Gruenenthal GmbH, Aachen, Germany aut NATIONALLICENCE 700 1- Tebbe Ulrich Medizinische Klinik II, Klinikum Lippe-Detmold, Germany aut NATIONALLICENCE 773 0- Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 3/4(1996-12-01), 385-390 0929-5305 3:4<385 1996 3 11239 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer